Novo Nordisk Launches Recombinant Blood Clotting Factor 8 Formulation In Japan
This article was originally published in PharmAsia News
Novo Nordisk launched Novoeight (turoctocog alfa), a recombinant blood clotting factor 8 formulation to suppress bleeding in hemophilia A patients, in Japan on May 12.
You may also be interested in...
Firm supplying all-in-one multivitamin blends rather than packs of multiple pills has four-member advisory board including digital marketing and consumer product marketing specialists and a health care strategist.
UK-headquartered company gets further backing from Novo Ventures and other investors convinced of the potential of NLRP3 inhibitors.
Mylan and Pfizer’s Upjohn have revealed a key date for their merger to create Viatris, after the deal set for midway through the year was pushed back recently due to the coronavirus pandemic.